Table 1 Characteristics of patients and controls and markers of r-axSpA disease activity before and after anti-TNF treatment
Patients | Controls | p | ||
|---|---|---|---|---|
N | 12 | 16 | ||
Males (N) | 7 | 11 | 0.7 | |
Median age, years (range) | 37 (22–52) | 37 (22–55) | 0.65 | |
Median disease duration since diagnosis, years (range) | 1 (0.5–25) | NA | ||
Median disease duration since symptom onset, years (range) | 6.5 (0.5–29) | NA | ||
HLA B27 positive, N (%) | 8 (66.7) | ND | ||
Baseline | Follow-up | |||
Mean CRP (SD), mg/dL | 0.58 (0.5) | 0.16 (0.2) | ND | |
Mean BASDAI (SD) | 6.3 (2) | 4.1 (1.7) | NA | |
Mean ASDAS (SD) | 3.2 (0.7) | 2.2 (0.6) | NA | |